Indivior PLC
LSE:INDV

Watchlist Manager
Indivior PLC Logo
Indivior PLC
LSE:INDV
Watchlist
Price: 932 GBX 1.91%
Market Cap: 1.2B GBX
Have any thoughts about
Indivior PLC?
Write Note

Indivior PLC
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Indivior PLC
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Indivior PLC
LSE:INDV
Total Receivables
$281m
CAGR 3-Years
16%
CAGR 5-Years
6%
CAGR 10-Years
4%
GlaxoSmithKline PLC
LSE:GSK
Total Receivables
ÂŁ7.8B
CAGR 3-Years
1%
CAGR 5-Years
2%
CAGR 10-Years
4%
AstraZeneca PLC
LSE:AZN
Total Receivables
$12.6B
CAGR 3-Years
23%
CAGR 5-Years
18%
CAGR 10-Years
4%
Verona Pharma PLC
NASDAQ:VRNA
Total Receivables
$12.5m
CAGR 3-Years
6%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Total Receivables
$965m
CAGR 3-Years
7%
CAGR 5-Years
7%
CAGR 10-Years
10%
Dechra Pharmaceuticals PLC
LSE:DPH
Total Receivables
ÂŁ176.2m
CAGR 3-Years
21%
CAGR 5-Years
17%
CAGR 10-Years
20%
No Stocks Found

Indivior PLC
Glance View

Market Cap
1.2B GBX
Industry
Pharmaceuticals

Indivior PLC, a pivotal player in the pharmaceutical landscape, traces its roots back to a dedicated focus on addiction treatment. With an origin steeped in addressing opioid dependency, the company carved out a significant niche by developing and marketing medication-assisted treatments. At the heart of Indivior's success is its flagship product, Suboxone, which combines buprenorphine and naloxone to manage opioid addiction. This formulation, integral in combating withdrawal symptoms and reducing the allure of opioids, positioned Indivior as an innovator in an era when the opioid crisis commanded urgent attention. The company's revenue model leverages the growing need for comprehensive drug dependence solutions, primarily driven by its robust portfolio of treatment options. By relentlessly advocating for effective healthcare policies and ensuring substantial product availability, Indivior maintains its competitive edge. The company's strategy is not just confined to novel drug development, but also focuses on expanding treatment access globally, aligning profitability with public health imperatives. This dual commitment to innovation and societal impact ensures that Indivior remains a significant force in the healthcare sector, adeptly navigating the complexities of addiction treatment while generating sustainable financial growth.

INDV Intrinsic Value
2 223 GBX
Undervaluation 58%
Intrinsic Value
Price

See Also

What is Indivior PLC's Total Receivables?
Total Receivables
281m USD

Based on the financial report for Jun 30, 2024, Indivior PLC's Total Receivables amounts to 281m USD.

What is Indivior PLC's Total Receivables growth rate?
Total Receivables CAGR 10Y
4%

Over the last year, the Total Receivables growth was 17%. The average annual Total Receivables growth rates for Indivior PLC have been 16% over the past three years , 6% over the past five years , and 4% over the past ten years .

Back to Top